ATE290877T1 - Stabilisierte insulin-zubereitungen - Google Patents

Stabilisierte insulin-zubereitungen

Info

Publication number: ATE290877T1
Authority: AT; Austria
Prior art keywords: insulin preparations; stabilized insulin; glycylglycine; analogue; citrate
Prior art date: 1998-01-09

Application number

AT99900206T

Other languages

English (en)

Inventor

Peter Langballe

Elsebeth Norup

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-09

Filing date

1999-01-06

Publication date

2005-04-15

1999-01-06 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2005-04-15 Application granted granted Critical

2005-04-15 Publication of ATE290877T1 publication Critical patent/ATE290877T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
102000004877 Insulin Human genes 0.000 title abstract 2
108090001061 Insulin Proteins 0.000 title abstract 2
229940125396 insulin Drugs 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 abstract 4
108010008488 Glycylglycine Proteins 0.000 abstract 2
229940043257 glycylglycine Drugs 0.000 abstract 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
239000000872 buffer Substances 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
229910001424 calcium ion Inorganic materials 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
229910001425 magnesium ion Inorganic materials 0.000 abstract 1
229910021645 metal ion Inorganic materials 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99900206T 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen ATE290877T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98610001		1998-01-09
PCT/DK1999/000006 WO1999034821A1 (en)	1998-01-09	1999-01-06	Stabilised insulin compositions

Publications (1)

Publication Number	Publication Date
ATE290877T1 true ATE290877T1 (de)	2005-04-15

Family

ID=8235844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99900206T ATE290877T1 (de)	1998-01-09	1999-01-06	Stabilisierte insulin-zubereitungen

Country Status (7)

Country	Link
US (1)	US6174856B1 (de)
EP (1)	EP1044016B1 (de)
JP (1)	JP2002500196A (de)
AT (1)	ATE290877T1 (de)
AU (1)	AU1870099A (de)
DE (1)	DE69924232D1 (de)
WO (1)	WO1999034821A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA984697B (en)	1997-06-13	1999-12-01	Lilly Co Eli	Stable insulin formulations.
US20020155994A1 (en) *	1997-10-24	2002-10-24	Svend Havelund	Aggregates of human insulin derivatives
PT1146896E (pt) *	1999-01-26	2002-10-31	Lilly Co Eli	Formulacoes monodispersas de analogo acilado e hexamerico insulina
WO2001052937A1 (en)	2000-01-24	2001-07-26	Medtronic Minimed, Inc.	Mixed buffer system for stabilizing polypeptide formulations
AUPQ633900A0 (en)	2000-03-20	2000-04-15	Jurox Pty Ltd	Anaesthetic composition
US20100129332A1 (en) *	2000-07-31	2010-05-27	Tamar Tennenbaum	Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) *	2002-07-09	2003-08-07	Tamar Tennenbaum	Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) *	2000-07-31	2006-11-16	Healor Ltd.	Methods and pharmaceutical compositions for healing wounds
DE60138572D1 (de) *	2000-07-31	2009-06-10	Univ Bar Ilan	Methoden und pharmazeutische zusammensetzungen zur wundheilung
US20040037828A1 (en)	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en)	2001-06-28	2004-05-18	Metronic Minimed, Inc.	Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20030158670A1 (en) *	2001-12-04	2003-08-21	Philip Hougaard	Method of planning and performing stability studies
AU2003208316A1 (en) *	2002-03-13	2003-09-22	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
AU2003218635A1 (en) *	2002-05-07	2003-11-11	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US20040126831A1 (en) *	2002-12-31	2004-07-01	Medtronic Minimed, Inc.	Functionalization of immobilized proteins
EP2107069B1 (de) *	2003-08-05	2013-01-16	Novo Nordisk A/S	Neuartige Insulinderivate
DK1651161T3 (da)	2003-08-07	2012-01-30	Healor Ltd	Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
CN103223160B (zh)	2004-07-19	2015-02-18	比奥孔有限公司	胰岛素-低聚物共轭物,制剂及其用途
CN101060856B (zh)	2004-11-22	2011-01-19	诺和诺德公司	可溶、稳定的含胰岛素制剂
ES2438145T3 (es)	2005-02-02	2014-01-16	Novo Nordisk A/S	Nuevos derivados de insulina
EP2452686A3 (de)	2005-08-29	2012-09-05	HealOr Ltd.	Verfahren und Zusammensetzungen zur Vorbeugung und Behandlung von diabetischer und alternder Haut
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
JP5202338B2 (ja) *	2006-02-27	2013-06-05	ノボ・ノルデイスク・エー／エス	新規インシュリン誘導体
BRPI0712041A2 (pt) *	2006-05-09	2011-12-27	Novo Nordisk As	derivado de insulina
US8796205B2 (en) *	2006-05-09	2014-08-05	Novo Nordisk A/S	Insulin derivative
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
CN101835486B (zh) *	2007-07-30	2012-12-12	希尔洛有限公司	用于治疗创伤的药物组合物以及相关方法
US9241908B2 (en) *	2007-10-16	2016-01-26	Biocon Limited	Orally administrable solid pharmaceutical composition and a process thereof
US8710000B2 (en) *	2007-11-08	2014-04-29	Novo Nordisk A/S	Insulin derivative
AU2009203809B2 (en)	2008-01-09	2013-07-25	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
EP2113564A1 (de) *	2008-05-01	2009-11-04	Arecor Limited	Proteinformulierung
TWI451876B (zh) *	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
FR2932908B1 (fr) *	2008-06-24	2012-11-16	Arjowiggins Licensing Sas	Structure comportant un filigrane ou pseudo-filigrane et un dispositif a microcircuit integre.
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
KR20110085985A (ko) *	2008-10-30	2011-07-27	노보 노르디스크 에이/에스	하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
WO2010088286A1 (en)	2009-01-28	2010-08-05	Smartcells, Inc.	Synthetic conjugates and uses thereof
BRPI1007457A2 (pt)	2009-01-28	2015-08-25	Smartcells Inc	Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
CA2754950A1 (en)	2009-03-20	2010-09-23	Smartcells, Inc.	Terminally-functionalized conjugates and uses thereof
US9018190B2 (en)	2009-03-27	2015-04-28	Adocia	Functionalized oligosaccharides
FR2943538B1 (fr)	2009-03-27	2011-05-20	Adocia	Formulation a action rapide d'insuline recombinante humaine
KR101853606B1 (ko) *	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
WO2011049776A1 (en) *	2009-10-22	2011-04-28	Cpex Pharmaceuticals, Inc.	Therapeutically effective preparations of insulin
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
EP2523677A2 (de)	2010-01-11	2012-11-21	Healor Ltd.	Verfahren zur behandlung von entzündungskrankheiten und -erkrankungen
US20120178675A1 (en) *	2010-07-07	2012-07-12	Biodel Inc.	Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
BR112013010345A2 (pt)	2010-10-27	2017-07-25	Novo Nordisk As	tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US20130231281A1 (en)	2011-11-02	2013-09-05	Adocia	Rapid acting insulin formulation comprising an oligosaccharide
US9381247B2 (en) *	2012-04-16	2016-07-05	Biodel Inc.	Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
ES2670969T3 (es)	2012-11-13	2018-06-04	Adocia	Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
US9707276B2 (en)	2012-12-03	2017-07-18	Merck Sharp & Dohme Corp.	O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
MX360420B (es)	2012-12-19	2018-10-31	Wockhardt Ltd	Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
BR112015013223A2 (pt)	2012-12-26	2017-07-11	Wockhardt Ltd	composição farmacêutica
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
AR099569A1 (es)	2014-02-28	2016-08-03	Novo Nordisk As	Derivados de insulina y los usos médicos de estos
US9795678B2 (en)	2014-05-14	2017-10-24	Adocia	Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr)	2014-05-14	2018-08-31	Adocia	Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TW201630622A (zh)	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
EP3261648B1 (de) *	2015-02-25	2023-12-06	Aerami Therapeutics, Inc.	Flüssige insulinformulierungen und verfahren dafür
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
JO3749B1 (ar) *	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr)	2015-11-16	2019-05-31	Adocia	Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
EP3518893A1 (de)	2016-09-29	2019-08-07	Arecor Limited	Neuartige formulierungen
KR20190140048A (ko)	2017-06-01	2019-12-18	일라이 릴리 앤드 캄파니	신속-작용 인슐린 조성물
EP3727424A4 (de)	2017-12-18	2021-10-27	Merck Sharp & Dohme Corp.	Konjugatbasierte systeme für kontrollierte insulinfreisetzung
WO2019125879A2 (en)	2017-12-18	2019-06-27	Merck Sharp & Dohme Corp.	Conjugate based systems for controlled insulin delivery
CA3094237A1 (en)	2018-04-04	2019-10-10	Arecor Limited	Medical infusion pump system for the delivery of an insulin compound
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
CA3173417A1 (en)	2020-03-31	2021-10-07	Alborz Mahdavi	Conjugates for selective responsiveness to vicinal diols
PH12023500012A1 (en)	2020-11-19	2024-03-11	Protomer Tech Inc	Aromatic boron-containing compounds and insulin analogs
US20230025595A1 (en) *	2021-07-13	2023-01-26	America Great Health, a California Corporation	Formulation and Method of Preparing Divalent Cation Charged Insulin for Oral Administration
WO2023225534A1 (en)	2022-05-18	2023-11-23	Protomer Technologies Inc.	Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU550068B2 (en) *	1981-03-10	1986-02-27	Novo Nordisk A/S	Zinc insulin stabilized with calcium or magnesium salts
PH23446A (en) *	1986-10-20	1989-08-07	Novo Industri As	Peptide preparations
JP2628340B2 (ja) *	1988-05-14	1997-07-09	株式会社いかがく	血液中のインシュリン成分の安定方法
DE3827533A1 (de) *	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE122006000015I1 (de) *	1993-06-21	2006-06-29	Novo Nordisk As	Asp-B28-Insulinkristalle
SI0792290T1 (en) *	1993-09-17	2001-12-31	Novo Nordisk As	Acylated insulin
JP3414539B2 (ja) *	1994-05-11	2003-06-09	有限会社ドット	経鼻吸収用組成物
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
DK0921812T4 (da) *	1996-06-20	2012-04-02	Novo Nordisk As	Insulinpræparater, som indeholder et halogenid

1999
- 1999-01-06 DE DE69924232T patent/DE69924232D1/de not_active Expired - Lifetime
- 1999-01-06 AU AU18700/99A patent/AU1870099A/en not_active Abandoned
- 1999-01-06 EP EP99900206A patent/EP1044016B1/de not_active Expired - Lifetime
- 1999-01-06 WO PCT/DK1999/000006 patent/WO1999034821A1/en not_active Ceased
- 1999-01-06 AT AT99900206T patent/ATE290877T1/de not_active IP Right Cessation
- 1999-01-06 JP JP2000527269A patent/JP2002500196A/ja active Pending
- 1999-01-07 US US09/227,053 patent/US6174856B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1044016A1 (de)	2000-10-18
US6174856B1 (en)	2001-01-16
JP2002500196A (ja)	2002-01-08
WO1999034821A1 (en)	1999-07-15
EP1044016B1 (de)	2005-03-16
AU1870099A (en)	1999-07-26
DE69924232D1 (de)	2005-04-21

Legal Events

Date	Code	Title	Description
2005-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69924232D1 (de)	2005-04-21	Stabilisierte insulin-zubereitungen
DK1175149T3 (da)	2003-03-17	Desinficerende sammensætning baseret på H2O2, syrer og metaliioner
CY1112687T1 (el)	2016-02-10	Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
BR9911724A (pt)	2001-03-20	Ciclosporina que tem um perfil de atividade melhorado
DE69024965D1 (de)	1996-02-29	Dehydrodidemnin b
PL330763A1 (en)	1999-05-24	Insulin preparations containing nacl
ATE310531T1 (de)	2005-12-15	Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung
NO20012994L (no)	2002-12-16	Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesieltdataobjekter i MMS-meldinger
NO20015471D0 (no)	2001-11-08	Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
SE8902532L (sv)	1991-01-15	Bestaemning av plasmaproteiner
DE69927795D1 (en)	2006-03-02	Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
NO20031860L (no)	2003-06-30	Kahalalid F
DK1178726T3 (da)	2003-06-10	Vandig opløsning til konservering af væv og organer
AU2001269575A1 (en)	2002-03-22	Nucleic acid sequences and proteins involved in cellular senescence
NO20024760D0 (no)	2002-10-03	Stabil og effektiv myk, fast antiperspirant og/eller deodorant
MY128230A (en)	2007-01-31	Antifungal composition
MXPA03002875A (es)	2003-07-14	Composicion de vacuna y metodo de estabilizacion.
DK1331940T3 (da)	2006-08-14	Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
MXPA03004539A (es)	2004-03-26	Luciferasas aisladas y uso de las mismas.
MY138219A (en)	2009-05-29	Biologically active peptides
HRP20020159B1 (en)	2007-08-31	Multi-dose erythropoietin formulations
GB2349150B (en)	2001-09-26	Expression of DNA or proteins in C. Elegans
AR024483A1 (es)	2002-10-02	Proteinas insecticidas y nematocidas
ATE238050T1 (de)	2003-05-15	4-cyano-4-deformylsordarizin-derivate
PL338704A1 (en)	2000-11-20	Derivatives of 4-cyano-4-deformylsordarin